Differential methotrexate toxicity between two human oral squamous carcinoma cell lines.

@article{Hanson1993DifferentialMT,
  title={Differential methotrexate toxicity between two human oral squamous carcinoma cell lines.},
  author={William G Hanson and Peter J. Ferguson},
  journal={The Journal of otolaryngology},
  year={1993},
  volume={22 3},
  pages={143-7}
}
Methotrexate is often used for induction or palliative therapy of advanced head and neck squamous cell carcinoma (HNSCC). However, resistance to this drug is a common clinical problem, which may be conferred by several mechanisms, including: i) decreased level of folate transport proteins, required for entry of methotrexate into cells, and ii) increase in amount of dihydrofolate reductase (DHFR), the target enzyme of this drug. Two established, clonal cell lines of HNSCC, having equal growth… CONTINUE READING